Dear Friends,

With a growing aging population, Alzheimer’s disease is becoming the greatest health issue facing our country.

The Centers for Disease Control and Prevention projects the burden of Alzheimer’s disease will nearly triple from over 5 million cases currently to 14 million by 2060. Alzheimer’s comes with great costs, both to society and to the patients and families who face the physical and emotional suffering associated with this disease.

Based on our belief that Alzheimer’s research was moving too slowly to address this rapidly growing problem, in 1998, we created the Alzheimer’s Drug Discovery Foundation (ADDF). Our mission was to speed up drug discovery and development. As a venture philanthropy, our business model has always been to think big, act bold, and support ideas others have shunned.

From day one, we were motivated to fund a diverse drug pipeline that extended beyond the traditional boundaries of Alzheimer’s drug research. These bold moves have led to new directions and novel discoveries that have changed, and continue to change, the face of Alzheimer’s research. Our work has caught the attention of important philanthropists, including Bill Gates and Jeff and MacKenzie Bezos, who in 2018 collaborated with us to develop the Diagnostics Accelerator, an initiative to fast-track both early Alzheimer’s detection and thereby the development of targeted treatments.

Twenty years later, the ADDF remains the only nonprofit organization that supports the development of such a wide array of innovative and novel Alzheimer’s drugs. Some of the agents we invested in a decade ago have progressed to human clinical trials that are going strong and are giving the entire field much hope. You will read about a few of these in this report. Now, more than ever, we are committed to advancing Alzheimer’s research by exploring drugs based on an understanding of the “biology of aging.”

Our success would not have been possible without the generosity of our donors. With their support, the ADDF to date has awarded $130 million to fund more than 600 Alzheimer’s drug discovery programs and clinical trials in 19 countries. In 2018 alone, the ADDF committed $20 million in 31 programs.

We see the next few years as a defining time for Alzheimer’s research. With better diagnostics, new knowledge, and over 100 drugs in clinical trials, we need to push forward the opportunities for drug discoveries.

We believe we will have new effective treatments for Alzheimer’s disease in our lifetime.

With our deepest thanks,

Leonard A. Lauder
Co-Chairman and Co-Founder

Ronald S. Lauder
Co-Chairman and Co-Founder
The Centers for Disease Control and Prevention projects the burden of Alzheimer’s disease will nearly triple from over 5 million cases currently to 14 million by 2060.

5.8 million
Americans currently living with Alzheimer’s

14 million
The number of Americans projected to be living with Alzheimer’s disease by 2060
Dear Friends,

I have been privileged to work alongside ADDF co-chairmen and founders Leonard A. Lauder and Ronald S. Lauder for the past 20 years in pursuit of safe, effective therapies for Alzheimer’s disease.

Over these two decades, the ADDF has been a forerunner in the attempt to conquer Alzheimer’s. We have cast a wide net globally, investing in promising ideas from both academia and biotechs—funding clinical trials that might otherwise not be supported.

To date, Alzheimer’s drug development efforts have been largely focused around beta amyloid plaques in the brain, a classic hallmark of Alzheimer’s disease. These attempts to address a single misfolded protein so far have not proven successful.

Given that aging is the leading risk factor for Alzheimer’s, the ADDF has taken a different approach. We have focused our efforts on translating the biology of aging into new treatments for Alzheimer’s.

Using the biology of aging as our blueprint, we are currently supporting the exploration of drugs that address the multitude of issues that could contribute to this complex disease. Included in this diverse pipeline are drugs aimed at neuroinflammation, vascular problems, epigenetics, synapse loss, and metabolic and mitochondrial dysfunction, among other aging malfunctions.

New therapeutics for Alzheimer’s disease will likely come from this understanding of the effects of aging on the brain. Ultimately, like other diseases of aging including cancer, diabetes and heart disease, it is likely a combination of drugs addressing multiple target pathways will be needed to effectively treat Alzheimer’s.

Moving forward, our efforts will continue to include the investigation of drugs designed to slow, stop, and possibly reverse disease progression, as well as drugs that address behavioral symptoms associated with Alzheimer’s. We are also interested in developing drugs aimed at disease prevention.

Critical to our success in finding effective ways to prevent and treat Alzheimer’s is the development of reliable, affordable, and accessible biomarkers—just as cholesterol is an early biomarker for heart disease. That is why the Alzheimer’s Drug Discovery Foundation created a coalition of leading philanthropists, including Leonard A. Lauder, Bill Gates, Jeff and MacKenzie Bezos, the Dolby family, and the Charles and Helen Schwab Foundation, among others, to create the Diagnostics Accelerator. Ultimately, with the right biomarker tools in place, we envision we will be able to take a personalized, precision medicine approach to Alzheimer’s treatment.

With the clear, courageous vision of our founders and the support of our donors, we have opened new avenues for Alzheimer’s drug discovery and have led the field in a new direction. By embarking on this broader course of research, we can hopefully make rapid progress in discovering the answers to help address, treat, and prevent the scourge of Alzheimer’s disease.

Many thanks for your partnership.

Howard Fillit, MD
Founding Executive Director and Chief Science Officer
Inside this report:

TRANSLATING THE BIOLOGY OF AGING INTO NEW THERAPEUTICS

06  Diversifying the Alzheimer’s Drug Pipeline
07  Combating the Build-up of Glutamate in Elderly Brains
08  Controlling Neuroinflammation and Loss of Brain Cell Connections
09  Applying Epigenetic Therapy to Treat Failing Memory
10  Diagnostics Accelerator: Support for Game-Changing Biomarkers

11  Cognitive Vitality: Prevention... And the Importance of Brain Health
12  New and Continuing Programs
18  2018 Event Highlights
20  Our Supporters
24  Leadership
26  2018 Financial Overview
DIVERSIFYING THE ALZHEIMER’S DRUG PIPELINE

It’s been known for some time that pathological changes occur in the brains of Alzheimer’s patients. It is clear to us that the development of brain plaques, or sticky clumps containing beta-amyloid protein, and tangles, consisting of a protein called tau, do not tell the whole Alzheimer’s story. With recognition of the intricacies of the disease and a heightened focus on the multitude of likely contributing factors, the ADDF is positioned to be on the cusp of important medical breakthroughs on the road toward developing potential therapies for the prevention and treatment of Alzheimer’s.

For decades, many Alzheimer’s drug development funders and scientists primarily focused on attempts to address one distinct abnormality observed in some aging brains: the development of plaques.

At the ADDF, we have historically taken a broader approach in our support of Alzheimer’s drug research. We know that aging itself is the leading risk factor for Alzheimer’s disease. And we recognize that the list of biological processes that can go awry in the aging brain is long, including the development of:

- Neuroinflammation
- Vascular problems
- Metabolic and mitochondrial changes within cells
- Epigenetic modifications, or alterations in gene regulation without shifts in the DNA sequence

More than ever, the ADDF understands that changes in any of these areas can place stress on brain cells, leading to loss of synapses (connections between brain cells) and resultant cognitive failure that is the hallmark of Alzheimer’s disease. As such, in 2018, we further advanced our drug development strategy tied to the biology of aging. We strengthened our commitment to supporting a far-reaching, diversified portfolio that includes drugs targeted toward multiple aging pathways. Novel research approaches now make up most potential treatments in clinical trials. Last year alone, we invested $20M to fund 31 new programs, supporting our multi-pronged approach to treating Alzheimer’s.

In this report we shine a spotlight on just a few examples of the exciting efforts the ADDF committed to in 2018. It is our hope that these studies will help answer important questions such as:

- Can an existing treatment for ALS, known as Lou Gehrig’s disease, also help prevent the cell-damaging accumulation of glutamate? Glutamate is an essential neurotransmitter for brain function, but during disease can express dangerously high levels, and even damage the cells, in elderly brains.
- Will a novel therapeutic agent be the answer for controlling the neuroinflammation and loss of brain cell connections that occur with age?
- Can the emerging field of epigenetics be applied to improve failing memory in aging brains?

Recognizing the complexity of Alzheimer’s disease, our goal moving forward is to uncover more than one drug—or combination therapies—that will likely be needed to treat and manage Alzheimer’s.
COMBATING THE BUILD-UP OF GLUTAMATE IN ELDERLY BRAINS

At the ADFD, part of our mission is to think outside the box. Among our drug development strategies is the exploration of existing agents approved for other diseases or conditions to determine whether any might also work to help Alzheimer's patients. This is called repurposing, which is the application of a drug approved for one indication to treat another. One such agent is riluzole, an approved drug for ALS—a rare disease that affects motor control and exhibits similar neurodegenerative characteristics to Alzheimer's.

One potential byproduct of aging is hyperactivity in the brain, which can be caused by excess levels of a brain chemical called glutamate. Normally, glutamate is essential for brain function, but in early Alzheimer's, glutamate levels are abnormally high and too much glutamate can damage brain cells. Dr. Ana Pereira, of the Icahn School of Medicine at Mount Sinai, has shown that a drug called riluzole can reduce excess levels of glutamate and can be repurposed as a potential treatment for early Alzheimer's. Dr. Pereira's team is currently testing riluzole in mild Alzheimer's patients.

With the help of $406,000 in ADFD funding, including $106,000 in 2018, Dr. Pereira and her team are conducting the first clinical trial of riluzole in patients with mild Alzheimer's disease. These funds have allowed Dr. Pereira to conduct brain imaging and cognitive testing to detect changes after six months of treatment. The study started at Rockefeller and expanded to Mount Sinai.

We look forward to Dr. Pereira reporting clinical results from this potentially exciting therapeutic approach to Alzheimer's.
CONTROLLING NEUROINFLAMMATION AND LOSS OF BRAIN CELL CONNECTIONS

Neuroinflammation and the loss of connections between brain cells have been found to be hallmarks of most neurodegenerative diseases, including Alzheimer’s. While there is still much to be learned concerning the link between inflammation and Alzheimer’s, the ADDF considers neuroinflammation to be an important area for drug discovery.

Fortunately, the outlook looks promising. A novel therapeutic known as MW150—developed by Dr. Martin Watterson, ADDF’s 2016 Goodes Prize winner—has shown efficacy in preclinical studies, a stage of research prior to human clinical trials—combating both neuroinflammation and loss of brain cell connections.

MW150’s exceptional performance in preclinical tests, including FDA-recommended preclinical safety studies, made it a promising candidate to move into clinical testing. In ADDF-supported Phase 1 research, MW150 became the first drug in the novel stress kinase inhibitor class to be tested in humans. This new class of drugs lowers levels of inflammatory cytokines, which damage neurons and can lead to the onset of Alzheimer’s.

The ADDF has supported the work of Dr. Watterson and Dr. Sakti Roy, of Northwestern University Feinberg School of Medicine, for almost 10 years. Dr. Watterson has teamed up with his collaborator, Dr. Ottavio Arancio of Columbia University School of Medicine, and others to form the biotech company Neurokine Therapeutics to further explore what could become a promising Alzheimer’s treatment.

ADDF has now awarded just over $1.6 million in funding to this project with $800,000 awarded in 2018 to Neurokine Therapeutics for the continuation of MW150 research. The funding will allow Neurokine to complete the Phase 1 clinical trial and perform the necessary work to move the program into larger Phase 2, the first in patient trials.
APPLYING EPigenetic Therapy TO TREAT failing MEMORY

In recent years, a new slant on research has piqued the interest of the Alzheimer’s research community. Epigenetics—the study of how genes are expressed (turned on and off) through mechanisms other than DNA, such as environment, stress, and diet—has emerged as an area ripe for exploration.

With time, epigenetic processes in the brain can become abnormal in response to environmental cues or stress and can have significant effects on the genes that control learning and memory. Left unchecked, neurodegeneration in the brain can occur.

With several investments from the ADDF, Oryzon Genomics developed a novel epigenetic inhibitor called ORY-2001 (vafidemstat) that shows promise as a means of improving memory and could play a role in the treatment of brain diseases.

After a successful Phase 1 clinical trial, ADDF has invested $15 million in Oryzon, to continue exploring the clinical potential of ORY-2001. With ADDF’s backing, Oryzon will expand their phase 2a multicenter, multinational 26-week trial, known as the ETHERAL study (Epigenetic THERapy in ALzheimer’s Disease), which will evaluate the safety, tolerability, and efficacy of ORY-2001 in patients with mild to moderate Alzheimer’s.

ADDF funding will expand the ORY-2001 trial, already begun in Europe, to support the U.S. arm of ETHERAL.
For cancer and heart disease, objective measurements of biological processes known as “biomarkers” (e.g., blood tests, wearable heart monitors, mammograms) serve as invaluable diagnostic tools. In the absence of reliable, cost-effective biomarkers to identify the presence of Alzheimer’s, diagnoses have frequently been based on cognitive tests.

The ADDF has long supported the development of Alzheimer’s biomarkers, including the first approved beta-amyloid PET scan (Amyvid®), along with novel PET agents and tests of cerebrospinal fluid (CSF). But these tests can be expensive and invasive.

Moreover, as more therapies with targets other than beta-amyloid and tau are developed—addressing a range of aging-related biological changes—we will need more novel, cost-effective biomarkers that can measure changes in these processes.

Acknowledging this unmet need, in 2018, the ADDF formed exciting new collaborations with a coalition of philanthropists including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff and MacKenzie Bezos, the Dolby family, the Charles and Helen Schwab Foundation, and The Association for Frontotemporal Degeneration, among others. Generous funding will enable us to award up to $50 million over the next three years to research aimed at developing cutting-edge Alzheimer’s biomarkers and novel diagnostic tools. These include blood tests, eye scans, and digital technologies, like app-based cognitive testing, that can measure multiple targets of aging biology associated with Alzheimer’s.

We believe that availability of reliable, affordable, and accessible diagnostic tools will potentially revolutionize our understanding of Alzheimer’s disease—allowing us to better understand how the disease progresses, identify the right people for clinical trials, and more accurately monitor their response to treatments.
COGNITIVE VITALITY

PREVENTION... AND THE IMPORTANCE OF BRAIN HEALTH

In the U.S., there are 46 million people estimated to have preclinical (presymptomatic) Alzheimer’s disease. Considering that medical advances delaying the onset of Alzheimer’s disease by five years may result in a 41% lower prevalence of Alzheimer’s, the ADDF believes a greater focus on prevention research is important to have a great impact on reducing the ravages of this disease.

Because we recognize that online education has the potential to reach a vast audience, we continued the development of our signature public education website, CognitiveVitality.org, first introduced in 2014. This site is developed and updated by ADDF’s Aging and Alzheimer’s Prevention program, whose mission is to evaluate, communicate, and accelerate the scientific evidence for different strategies to prevent brain aging, Alzheimer’s disease, and related dementias.

Our team of neuroscientists evaluates and writes about the scientific evidence for and against the safety and efficacy of select foods, drinks, vitamins, supplements, and drugs. Our goal is to provide balanced scientific information, updated regularly, to improve decision making by patients, physicians, and caregivers. Other contents of Cognitive Vitality include first steps to protect your brain health and blog posts on news related to dementia risk and prevention. Recognized for his expertise in this area, the ADDF’s Dr. Howard Fillit, among other scientists, doctors, scholars and policy experts, was invited to participate in a panel hosted by the AARP Global Council on Brain Health (GCBH) in 2018 to examine the evidence and gain consensus on whether dietary supplements can impact people's cognitive functions. In addition to these expert discussions, the GCBH relied on information and material from the ADDF and CognitiveVitality.org as well as other reputable websites to develop a comprehensive report.

In 2018, the ADDF furthered our commitment to Alzheimer’s prevention education and CognitiveVitality.org has acted as a catalyst of several important programs. We collaborated with Richard Isaacson, MD, Director of the Alzheimer’s Prevention Clinic at Weill Cornell Medicine, who is also an expert on online education and e-learning. Dr. Isaacson and his team have built web-based brain health lessons for the lay audience as well as for healthcare professionals, the latter of which were accredited by Continued Medical Education (CME). These web-based lessons were based on information available on Cognitive Vitality. Because of their interactive nature they are designed to increase the amount of knowledge gained as well as the retention of information by people taking the lessons.

We also supported UsAgainstAlzheimer’s in their Brain Health Ecosystem Project, which has a goal of developing and advancing the brain health standard of care. Toward this effort, they convened several conferences of key opinion leaders and launched their Campaign for Women’s Health to empower women to take informed actions to promote the brain health of themselves and their families.
NEW AND CONTINUING PROGRAMS IN 2018

* Indicates Addf support of different programs led by the same researcher

**VASCULAR**

Healthy blood flow is essential for providing neurons with sufficient oxygen and vital nutrients. These researchers are targeting vascular damage to improve brain function.

- **Sandra Black, MD**
  - University of Toronto
  - Clinical Phase 2
  - $1,442,388

- **Atticus Hainsworth, PhD**
  - St. George’s University of London
  - Clinical Phase 2
  - $464,992

**SYNAPTIC ACTIVITY AND NEUROTRANSMITTERS**

Neurotransmitters carry signals across synapses, which are connections between neurons. These processes are critical for memory and cognition.

- **Susan Birren, PhD**
  - Brandeis University
  - Preclinical Testing
  - $461,910

- **Barbara Borroni, MD**
  - University of Brescia
  - Clinical Phase 2
  - $90,000

- **Mauro Costa-Mattioli, PhD**
  - Baylor College of Medicine
  - Target Validation
  - $150,000

- **Jeffrey Cummings, MD**
  - Cleveland Clinic
  - Clinical Phase 2
  - $1,228,000

- **Michela Gallagher, PhD**
  - AgeNeBio, Inc.
  - Clinical Phase 3
  - $150,000

**Narayan Bhat, PhD**
- Medical University of South Carolina
- Preclinical Testing
- $230,961

**Ihab Hajjar, MD**
- Emory University
- Clinical Phase 2
- $973,777
Giacoimo Koch MD, PhD
Santa Lucia Foundation
Clinical Phase 2
$250,000

Chien-liang Lin, PhD
Ohio State University
Lead Optimization
$640,164

Paul Newhouse, MD*
Vanderbilt University Medical Center
Clinical Phase 1
$1,271,774

Ana Pereira, MD
Icahn School of Medicine at Mount Sinai
Clinical Phase 2
$406,000

Dianne Perez, PhD
Cleveland Clinic Foundation
Lead Optimization
$381,340

Jerri Rook, PhD
Vanderbilt Center of Neuroscience
Drug Discovery
Preclinical Testing
$150,000

Sharon Rosenzweig-Lipson, PhD*
AgenBio, Inc.
Clinical Phase 3
$798,087
&
Lead Optimization
$750,000

Thota Ganesh, PhD
Emory University
Preclinical Testing
$314,700

Milton Greenberg, PhD
Vivrecon Biosciences, LLC
Lead Optimization
$150,000

Clive Holmes, PhD
University of Southampton
Clinical Phase 2
$533,330

Masashi Kitazawa, PhD
University of California, Irvine
Preclinical Testing
$328,000

Alexandros Makriyannis, PhD
Northeastern University
Lead Optimization
$425,000

Christopher Norris, PhD
University of Kentucky Research Foundation
Preclinical Testing
$257,552

John Olichney, MD
University of California, Davis School of Medicine
Clinical Phase 2
$434,991

Michael Parker, DPhil, FAA, FAHMS
St. Vincent’s Institute of Medical Research
Screening
$345,754

Paolo Pevarello, PhD
Axaxm SpA
Lead Optimization
$300,000

Paul Thompson, PhD
University of Massachusetts Medical School
Preclinical Testing
$150,000

D. Martin Watterson, PhD
NeuroKine Therapeutics
IND-Enabling
$150,000

Manfred Windisch, PhD
NeuroKine Therapeutics
Clinical Phase 1
$860,500

Shijun Zhang, PhD
Virginia Commonwealth University
Preclinical Testing
$130,000

Danna B. Zimmer, PhD
University of Maryland School of Medicine
Preclinical Testing
$150,000

*To date, no investors have been named.
These investments include comparative effectiveness and clinical research of prevention strategies to lower the risks of developing dementia.

Deborah Blacker, MD, ScD
Harvard Medical School
$25,000

Marek Brzezinski, MD, PhD
University of California, San Francisco
$300,000

Sharon Inouye, MD, MPH
Hebrew SeniorLife
$1,069,609

Richard Isaacson, MD
Weill Medical College of Cornell University
$100,000

Kejal Kantarci, MD, MS
Mayo Clinic Rochester
$66,094

Lenore Launer, PhD
Intramural Research Program, National Institute on Aging
$80,264

Nathalie Pochet, PhD
Brigham & Women’s Hospital
$135,000

Phillip Tully, PhD, Mpsych, BHSc
University of Adelaide
$99,363

Bruno Vellas, MD
Toulouse Centre of Excellence in Neurodegeneration, University Hospital Toulouse
$300,000

Galit Weinstein, PhD
University of Haifa, Israel
$82,789

Kristine Yaffe, MD
University of California, San Francisco
$100,000

George Vradenburg
UsAgainstAlzheimer’s Network
$1,000,000

Valina Dawson, PhD
Johns Hopkins School of Medicine
Lead Optimization
$167,858

Pontus Forsell, PhD
AbeCure Foundation
Lead Optimization
$456,905

Thomas Franke, MD, PhD
Icahn School of Medicine at Mount Sinai
Lead Optimization
$256,435

Justin Ichida, PhD
University of Southern California
Preclinical Testing
$150,000

Leen Kawas, PhD
M3 Biotechnology, Inc.
Clinical Phase 1
$1,397,530

Frank Longo, MD, PhD
PharmantriX
Clinical Phase 2
$650,000

Michael Peel, PhD
Cyparis Ltd
Lead Optimization
$523,940
Irina Pikuleva, PhD
CWRU School of Medicine
Clinical Phase 2
$794,596

William Ray, PhD
MD Anderson
Lead Optimization
$538,620

Scott Sneddon, PhD
Sharp Edge Labs, Inc.
Assay Development
$488,800

Grace Stutzmann, PhD
NeuroLucent & Chicago Medical School
Lead Optimization
$566,927

Sung Ok Yoon, PhD
Ohio State University
Preclinical Testing
$200,802

Yan Zhang, PhD
The University of Texas at Austin
Lead Optimization
$350,000

Christopher Hulme, PhD
University of Arizona
Lead Optimization
$99,964

Janice Kranz, PhD
Elkonizo Therapeutics, Inc.
Clinical Phase 1
$841,062

Thomas Kukar, PhD
Emory University
Preclinical Testing
$350,000

Salvatore Oddo, PhD
Banner Sun Health Research Institute
Preclinical Testing
$42,000

Yukari Perrella, MBA
Yuma Therapeutics Corporation
IND-Enabling
$456,174

Brent Stockwell, PhD
Columbia University
Lead Optimization
$120,000

Raymond Scott Turner, MD, PhD
Georgetown University
Clinical Phase 2
$2,104,000

Xinglong Wang, PhD
Case Western Reserve University
School of Medicine
Screening
$350,000

**MISFOLDED PROTEINS**

These scientists are pursuing approaches to prevent or clear the accumulation of misfolded proteins, which causes damage to brain cells.

**BIOMARKERS**

Biomarkers are tools used to diagnose a disease and assess its progression and response to treatment. These researchers aim to develop more accurate biomarkers for clinical trials.

Adam Boxer, MD, PhD
University of California, San Francisco
$75,000

Massimo Filippi, PhD
Fondazione Centro San Raffaele
$125,000

Sam Gandy MD, PhD
Icahn School of Medicine at Mount Sinai
$187,069
As we age, mitochondria, the energy center of our cells, can become impaired. These researchers are developing drugs targeting this dysfunction.

**MITOCHONDRIA AND METABOLIC FUNCTION**

- **Neil Vasdev, PhD**
  Massachusetts General Hospital
  $331,805

- **Paul Worley, MD**
  Johns Hopkins School of Medicine
  $160,000

- **Ying Wu, MD**
  NorthShore University HealthSystem Research Institute
  $85,300

**GENETICS AND EPIGENETICS**

- **Gary Gibson, PhD**
  Burke Medical Research Institute
  Clinical Phase 2
  $750,000

- **Eugenia Trushina, PhD**
  Mayo Clinic Rochester
  Lead Optimization
  $900,000

- **Bradley Hyman, MD, PhD**
  Harvard Medical School
  Preclinical Testing
  $250,000

- **Kent Leslie, Msc**
  Amylyx Pharmaceuticals, Inc.
  Clinical Phase 2
  $928,234

- **Berkley Lynch, PhD**
  Rodin Therapeutics
  Preclinical Testing
  $161,759

- **Pavel Petukhov, PhD**
  University of Illinois at Chicago
  Lead Optimization
  $142,100

- **Evgeny Rogachev, PhD**
  University of Massachusetts - Lowell
  Preclinical Testing
  $342,429

- **Xiang (Simon) Wang, PhD**
  Howard University College of Pharmacy
  Screening
  $110,000

- **Miles Berger, MD, PhD**
  Duke University Medical Center
  Clinical Phase 2
  $1,631,197

- **Ronald Crystal, MD**
  Weill Medical College of Cornell University
  Clinical Phase 1
  $3,006,472

**Tamara Maes, PhD**
Oryzon Genomics SA
$300,000

**Gerard Nuovo, MD**
Gnome Diagnostics, LLC
$181,750

**Blaine Roberts, PhD**
Howard Florey Institute
$149,518

**Dennis Selkoe, MD**
Brigham & Women's Hospital
$307,792

**Keith St Lawrence, PhD**
Lawson Health Research Institute
$163,626

**Peter Stys, MD**
University of Calgary
$293,369
Richard Moehs, PhD
Global Alzheimer’s Platform Foundation
$100,000

Meredith Upton
Foundation for the National Institutes of Health, Inc.
$100,000

Michael Weiner, MD
University of California, San Francisco
$100,000

Alison Drone, MA
Foundation for the National Institutes of Health, Inc.
$5,000

Edward Huey, MD
Columbia University
Clinical Phase 2
$532,335

Krista Laumont, PhD
Sunnybrook Research Institute, University of Toronto
Clinical Phase 2
$229,284

Joe Menetski, PhD
Foundation for the National Institutes of Health, Inc.
$50,000
2018 EVENT HIGHLIGHTS

PREMIERE HOPE ON THE HORIZON
PALM BEACH LUNCHEON
March 13, 2018 | Palm Beach
Hosted by actress and philanthropist Jane Seymour, this event honored Kim Campbell, founder Careliving.org

MEMORIES MATTER
April 10, 2018 | New York City
Guests discussed the latest advances in Alzheimer’s research over dinner while enjoying musical guest The Nancy Atlas Project and bidding on a silent auction

EIGHTH ANNUAL
GREAT LADIES LUNCHEON AND FASHION SHOW
April 18, 2018 | Washington D.C.
Hosted by CNN Lead Political Anchor Wolf Blitzer, this event honored the Neiman Marcus Group, with a special runway show by Etro
2018 EVENT HIGHLIGHTS

Twelfth Annual
CONNOISSEUR’S DINNER
May 3, 2018 | New York City
Annual Gala honoring Fabrizio Freda, President and CEO, The Estée Lauder Companies, featured an exclusive art preview and wine pairings.

Fourth Annual
MELVIN R. GOODES PRIZE
September 17, 2018 | New York City
We were proud to present the 2018 Melvin R. Goodes Prize to Michela Gallagher, PhD.

Ninth Annual
FALL SYMPOSIUM AND LUNCHEON
November 2, 2018 | New York City
With a theme of “Hope on the Horizon” our luncheon honored David R. Weinreb.
$1,000,000 AND ABOVE
Anonymous (2)
Association for Frontotemporal Degeneration
Charles and Helen Schwab Foundation
Dagmar Dolby Fund
Foundation for a Better World
Gates Ventures
Judy and Leonard A. Lauder

$500,000 - $999,999
David A. and Mildred H. Morse Charitable Trust
Roslyn Goldstein
Jo Carole and Ronald S. Lauder
Joan Sutton Straus

$250,000 - $499,999
Natasha and David Dolby
Susan and Thomas Lowder
Catherine and Michael Podell
The S Family Charitable Foundation

$100,000 - $249,999
Carol and Jack Aten
Julie and Philip Geier
Nancy and Melvin R. Goedes
The Harmes C. Fishback Foundation Trust
Frances and Nathan Kirsh
Lattner Family Foundation
The Lefkofsky Family Foundation
Phoebe and Edwin Rice
Samuel I. Newhouse Foundation, Inc

Lizabeth Furman Sandler and Randal Sandler
David R. Weinreb
Carolyn and Malcolm Wiener

$50,000 - $99,999
A.P. Kirby, Jr. Foundation, Inc
Andrew and Ann Tisch Foundation, Inc
Bloomberg Philanthropies
The Chisholm Foundation
Caryn J. Clayman
Joyce Cowin
Wendy Wilshin and Ronald Dickerman
Eli Lilly and Company
Mindy and Jonathan Gray
J. Christopher and Anne N. Reyes Foundation
Krehbiel Family Foundation
Laura and Gary M. Lauder
William P. Lauder
Laurence C. Leeds, Jr.
Elise and Marc Lefkowitz
Margaret and Daniel Loeb
Andrea and Jeffrey Lomasky
Melvin R. Goedes Family Foundation
Marsha Perreault
Pershing Square Capital Management
Ann and Andrew Tisch

$25,000 - $49,999
Anonymous
A.T. Kearney, Inc
Arkay Packaging

Beacon Trust
BlackRock
Carol Seabrook Boulanger
Melanie and Louis Caceres
The Calvin Klein Family Foundation
Annette and Charles Congro
Continental Grain Company
Deloitte
Cynthia Breen and Laurie Dowley
Annette and Mitchell Eichen
Ernst and Young LLP
Mary C. Farrell
The Firmsenich Charitable Foundation
First Republic Bank
Marilyn and Sam Fox
Mary-Ann and Fabrizio Freda
Paula Zahn and Paul Frilbourg
Givaudan Fragrances Corporation
Michal Grayevsky
Elizabeth and Paul Greenbaum
Gloria Greenbaum
Bobba Paul Hauserman
Hearst Corporation
Hertog Foundation, Inc
The IFF Foundation Inc
Intercos America
Rose Marie Bravo and William Jackey
JP Morgan Chase
Amy and Mitchell Kanef
KLD Foundation
Randi and Clifford Lane
Bonnie Englebardt Lautenberg
Beatrice Liu and Philip Lovett
Macy’s, Inc
Nancy and Howard Marks
Merck
Northern Trust
Nucor Construction Corp
Thomas Pheasant
Sharon and Robert Prince
The Ralph and Ricky Lauren Family Foundation, Inc
Amy and James Regan
Thomas Scanlan
Janet and Charles Seidler
Trish and Steven Shapiro
Mia and Sheldon Solow
Sotheby’s
Jan Willinger and Robert Spiegel
Staples Business Advantage
Mimi and Barry Sternlicht
Thomas W. Smith Foundation
Tishman Speyer Properties, LP
The Toma Family
George A. Vradenburg III
Carol and Michael Weisman
Lois Robbins and Andrew Zaro

$10,000 - $24,999
Anonymous (3)
Pennie and Gary Abramson
Hope and Marc Altheim
Jennifer and Claude Amadeo
Judy Angelo
Aon Foundation
Aon Risk Services, Inc of Hawaii
Shelley and Robert Banks
Renée and Robert Belfer
Judy and Howard Bernick
Claire Foerster and Daniel S. Bernstein
BGE, Inc
Marta Gucovsky and Edward Blank
Faith Bobrow
Terry Boyer
James Buller
Linda and Arthur Carter
CBRE
Kristin and John Cecchi
Clifford Chance US LLP
Michael T. Cohen
Colliers International
Kurt and Gina Conti
Nancy Coszline
Mary Quick and James Daras
John D. Demsey
Beth Rudin DeWoody
Dongah Elecomm Corporation
Donovan LLP
Edgewood Management LLC
Forrester Bernstein Foundation
Fried, Frank, Harris, Shriver and Jacobson LLP
Gardiner and Theobald Inc
Georgia Melenikotou-Garinali and Philippe Garinios
Gensler
Stephanie and Ian Ginsberg
Goldman Sachs
David Goodes
Phyllis E. Grann
Audrey and Martin Gruss
Ann Zimmerli-Haskell and James Haskel
Karlyn and Grant Herlitz
Hess Philanthropic Fund
Paul Hilal
William M. Hitchcock
Shelley and Allan Holt
Joanna Horgan
Jane Hertzmark Hudis and Clifford Hudis
Hudson’s Bay Company
Hues for You, LLC
Inoac Packaging Group Inc
Irwin S. and Bryna Monsein Philanthropic Fund
Amy and Scott Jaffee
John Q. O’Donnell Interests
Katy Kamen
Yue-Sai Kan
Cherry and Howard Kaneff
Jill and Craig Koenigberg
David H. Komansky
Deborah and Peter Krulwich
Dana and Michael Landow
Judy Lauder
Laurie M. Tisch Illumination Fund
Raymond Leary
Carole Cooper and Richard Leibner
Sheri and Seth Leist
Carol and John Levy
Serena and John Liew
Louis J. and June E. Kay Foundation
May and Samuel Rudin Family Foundation
Julie Medler
Elaine and William Miller
MorseLife Health System, Inc
Jennifer Myerberg
Pamela J. Newman
Mr. and Mrs. Michael Nierenberg
Christina and Michael O’Hare
Julie Chrystyn Opperman
Otsuka Pharmaceutical Development and Commercialization, Inc
Pfizer Inc
Porphyry Road Foundation
Phebe Farro Port and Thomas David Port
Cobey Rapaport
Lori and John Reinsberg
Denise Rich
Sheila J. Robbins
Robert and Ardis James Foundation, Inc
Sharon and Daniel Roitman
Patricia Sagon
Laura Landro and Richard Salomon
Saul Scherl
Susan and Stephen Scherr
Finley and Patrick Shaw
Glenn Sherrill, Jr.
Klara and Larry Silverstein
Iris Smith
Stewart Commercial Services
Susan Zises Green, Inc ASID
Gerald Swartz
Sharon Sager and J. Loring Swasey
The Nate and Ann Levine Family Foundation
Nikola and Milton Theo

Maria Hummer-Tuttle and Robert Tuttle
Lorraine Wallace
William K. Bowes, Jr. Foundation
Cathy Williams
Allison and Boniface Zaino
Marlene Hess and James Zirin

$5,000 - $9,999
Daniel Abraham
Alliance Bernstein LP
Barbara and Philip Althheim
Arcade Beauty
Shari and Jeff Aronson
Ruth Baum
Willa and Robert Baynard
Lisa and Clifford Beek
Grace and Morton Bender
Bender Foundation, Inc
Clifford Berger
Barbara and Bruce Berger
Seth Bernstein
Mark Bilski
Laura and Lloyd Blankfein
Lynn and Wolf Blitzer
Alexandra and Olivier Bottrie
Susan and Jonathan Bram
Bramshill Investments, LLC
Evelyn Brandt
Lisa Brittz
Broadridge Financial Solutions
Estrellita and Daniel Brodsky
Nancy and Alan Bubes
Lynda and F. Davis Camalier

The Carl M. Freeman Foundation
Cipriani USA Inc
Roberto Coin
Jeanne Coleman
Corcoran Group Real Estate
The Corcoran Group
Credit Suisse
Wyatt Crowell
Ellen Davin
Veronica and John DeBruin
DFS Group Limited
Douglas DiPasquale
Nancy E. and Marc N. Duber
Cindy and Glen Edelman
Ellington Management Group
Peter Engel
Janet and Peter Ezersky
Betty and David Farrell
Father’s Day/Mother’s Day Council, Inc
Faucet Face
Sheri and Marc Feigen
Fleet Miami
Tom Ford
Andrew Friedwald
Barbara and Richard Furman
Judith and Howard Ganek
Julie Garcia
David Gerson
Carol and Henry Goldberg
David A. Goldberg
Marjorie and Ellery Gordon
Andrea and James Gordon
Sara Moss and Michael Gould
Janet and Allan Green
Alyssa and Cliff Greenberg
Flora Greenberg
Laurie and Philip Gross
Sarah and Geoffrey Gund
Hamilton Jewelers
Ani and Carl Haney
Madelyn and Steven Harris
HeySun Oy
Hoar Construction
Ibex Investors, LLC
Eli S. Jacobs
Lynnette and Richard Jaffe
John L. and Sue Ann Weinberg Foundation
Kiara and Christopher Johnson
Cindy Jones
JP Morgan
Carolyn Keller
Vicki and Christopher Kellogg
Eleanor R. Kennedy
Howard Kessler
Nancy Kestenbaum and David Klafter
Korn Ferry
Nicole Kubin
Latham and Watkins LLP
Ellen Levy
Linda and Steven Levy
Toby Devan Lewis
Randy and Jeffrey Liebenthal
Linda H. Lindenbaum
Alexandra Trover Lindsey and Jon Lindsey
Susan Lloyd
Allison and Howard Lutnick
The Marc Haas Foundation
Margrave Strategies
Pamela and Tony Marquez
Marsh and McLennan Companies
David Martin
Roni and Charles McGuffog
Merrill Lynch
Beverly Griffin Michel and Marc Michel
Moët Hennessy USA
Lisa and Mark Neporent
Melanie and Lawrence Nussdorf
The Parsons Family Foundation
Kathleen and Michael Pierce
Jill Podell
Porter Family Charitable Foundation, Inc.
Providence Equity LLC
Donna and Charles Reilly
Rick Sharp Alzheimer’s Foundation
Lisa Ritter-Kahn
Donna and William Roberts
Janet C. Ross
Darryl and Steven Roth
Royal Abstract
Stacy and Kenneth Samet
Gillian Sandler
Edith and Gerald Schaeffer
Benjamin Schall
María Mostajo and Mark Schein
Dr. and Mrs. Dale Schenk
Joan and George Schiele
June and Paul Schorr
Diane and John Sculley
Hadley and John Scully
Sephora
Ricky Seung
Stuart Sherrill
Jill and Sanford Sirulnick
Diane Krane and Myles Slosberg
Karen and Spencer Smul
Societe Generale
Susan and Peter Solomon
South Dakota Trust Co.
The Starker Family Foundation
Marianne and Roger Staubach
Karen and Marc Taub
Tanya and David Tisch
Barbara and Donald Tober
Tracey Travis
Suzanne and Vincent Tufariello
Diane and Thomas Tuft
U.S. Bank
Sadye and Alan Waldenberg
Suzanne Walken
Sara and John Walsh
Washington Fine Properties
Ellen and David Wasserman
Renata and Alexander Weiss
Wells Fargo Bank
Wilson Okamoto Corporation
Janice Worth
Sharon and Michael Young
LEADERSHIP

BOARD OF GOVERNORS

The Board of Governors is the principal board of the Corporation with all legal power and authority to manage, oversee, and make decisions regarding the ADDF’s programs and activities. Board members include leaders from government, industry, and the research community who serve as ambassadors for the ADDF and provide strategic oversight and counsel.

* Denotes Honorary Members

ADDF HONORARY CHAIR
Justice Sandra Day O’Connor
(Retired) Associate Justice, US Supreme Court

CO-CHAIRMEN
Leonard A. Lauder
Chairman Emeritus, The Estée Lauder Companies Inc

Ronald S. Lauder
Chairman, Clinique Laboratories, LLC

Randal Sandler
Director of Client Services and Marketing, Bridgewater Associates

EX OFFICIO
Howard Fillit, MD
Founding Executive Director and Chief Science Officer

TREASURER
Kevin Dieterich
Vice President, Executive Financial Management, Estée Lauder Companies

ASSISTANT TREASURER AND SECRETARY
Lisa Somar
Vice President, Executive Financial Management, Estée Lauder Companies

Robert Belfer
Chairman, Belfer Management

Nancy Corzine
President and CEO, Nancy Corzine Inc

Roberta Diaz Brinton, PhD
Director, UA Center for Innovation in Brain Science at the University of Arizona Health Sciences

Lanny Edelsohn
Director, Christiana Care Health Systems, Inc

Melvin R. Goodes*
Former Chairman and CEO, Warner-Lambert

Nancy Goodes
Former Executive, Nazareth-Century Mills; Secretary, Melvin R. Goodes Family Foundation, Inc

Gary M. Lauder
Managing Director, Lauder Partners LLC

Laurence Leeds
Chairman, Buckingham Capital Management, Inc

Bruce McEwen, PhD
Alfred E. Mann Professor, The Rockefeller University

Thomas McWilliams
Managing Partner, Court Square Capital Partners

Richard Mohs, PhD
Chief Scientific Officer, Global Alzheimer’s Platform Foundation; Vice President of Clinical Development, Agenebio, Inc

Steven Marc Paul, MD
Chief Executive Officer and Chairman of the Board for Karuna Pharmaceutical

Bonnie Pfeiffer Evans
Senior Sales Associate, Corcoran Group Real Estate; Co-Trustee, The Charles Evans Foundation

Alice Shure
Founder and Producer, AMICI Productions LLC; Co-Trustee, The Charles Evans Foundation

Sally Susman*
Executive Vice President, Policy, External Affairs and Communications, Pfizer Inc

Paula Zahn
Host and Executive Producer, Discovery ID’s “On the Case with Paula Zahn,” and WNET’s “NYC Arts”

All Members as of December 31, 2018
LEADERSHIP

BOARD OF OVERSEERS

The Board of Overseers is an advisory body committed to providing counsel and support to the ADDF Board of Governors and staff. Overseers lend their expertise to advance the ADDF’s mission to accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease. Overseers are appointed by and serve at the pleasure of the Board of Governors.

CHAIR
Sharon Sager, CIMA
Managing Director and Private Wealth Advisor, UBS Private Wealth Management

Carol Boulanger
Partner, Pillsbury, Winthrop, Shaw, and Pittman, LLP

Charles Cangro
Principal, Personal Financial Services, Ernst & Young

Mitchell Eichen, JD, LLM
Founder and Chief Executive Officer, Acertus Capital Management

Stephanie Ginsberg
Volunteer, Philanthropist; Founder, BCRF Pink Promises Benefit

Allan M. Green, MD, PhD, JD
Allan M. Green Esq., LLC

Christopher Johnson
President and Managing Officer, Rackson Corporation

Bonnie Lautenberg
Photographer, Writer

Elise Lefkowitz
Philanthropist

Phil Lovett
Founding Partner, Millennium Partners

Julie Medler
Managing Director, Golden Seeds

Pamela Newman, PhD
President and Chief Executive Officer, The Newman Team, Aon Corporation

Phebe Farrow Port
Senior Vice President, Global Management Strategies and Chief of Staff, Executive Management Initiatives, The Estée Lauder Companies Inc

Thomas Scanlan
Partner, Spencer Stuart

John Scully, CIMA
Senior Managing Director, Head of Private Wealth Advisory, Nuveen Investments

Stephen Toma
Managing Director, VJMS, LLC

Wendy Wilshin
Founder and Principal, WLW Designs

All Members as of December 31, 2018
# 2018 Financial Overview

*Full audited 2018 financials available by request*

## Statement of Financial Position

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash &amp; cash equivalents</td>
<td>$ 6,688,572</td>
<td>4,281,702</td>
</tr>
<tr>
<td>Investments, at fair value</td>
<td>47,708,468</td>
<td>26,571,127</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>35,523,444</td>
<td>14,902,876</td>
</tr>
<tr>
<td>Due from Institute for the Study of Aging, Inc</td>
<td>-</td>
<td>86,761</td>
</tr>
<tr>
<td>Other assets</td>
<td>117,739</td>
<td>130,943</td>
</tr>
<tr>
<td>Total Assets</td>
<td>90,038,223</td>
<td>45,973,409</td>
</tr>
</tbody>
</table>

## Liabilities & Net Assets

<table>
<thead>
<tr>
<th>Liabilities</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable &amp; accrued liabilities</td>
<td>12,203</td>
<td>33,368</td>
</tr>
<tr>
<td>Grants payable</td>
<td>29,988,071</td>
<td>25,433,267</td>
</tr>
<tr>
<td>Due to Institute for the Study of Aging, Inc</td>
<td>168</td>
<td>-</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>103,900</td>
<td>199,247</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>30,104,342</td>
<td>25,666,082</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net Assets</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without donor restrictions</td>
<td>24,729,290</td>
<td>5,226,704</td>
</tr>
<tr>
<td>With donor restrictions</td>
<td>35,204,591</td>
<td>15,080,533</td>
</tr>
<tr>
<td>Total net assets</td>
<td>59,933,881</td>
<td>20,307,327</td>
</tr>
</tbody>
</table>

| Total liabilities & net assets                  | $ 90,038,223 | 45,973,409 |

## Statement of Activities

### Change in Net Assets

<table>
<thead>
<tr>
<th></th>
<th>2018 Without Donor Restrictions</th>
<th>2018 With Donor Restrictions</th>
<th>2017 Total</th>
<th>2017 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Support &amp; Revenues</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions &amp; grants</td>
<td>$ 6,003,608</td>
<td>$44,106,822</td>
<td>$50,110,430</td>
<td>$10,011,228</td>
</tr>
<tr>
<td>Contributions of in-kind services from the Institute for the Study of Aging, Inc</td>
<td>3,665,626</td>
<td>-</td>
<td>3,665,626</td>
<td>3,502,147</td>
</tr>
<tr>
<td>Proceeds from special events, net of direct expenses</td>
<td>4,043,790</td>
<td>-</td>
<td>4,043,790</td>
<td>3,266,247</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>24,004,122</td>
<td>24,004,122</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Revenues:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grant returns</td>
<td>1,111,911</td>
<td>21,358</td>
<td>1,133,269</td>
<td>568,283</td>
</tr>
<tr>
<td>Conference registration fees &amp; other income</td>
<td>151,293</td>
<td>-</td>
<td>151,293</td>
<td>187,548</td>
</tr>
<tr>
<td>Investment Income</td>
<td>378,458</td>
<td>-</td>
<td>378,458</td>
<td>361,984</td>
</tr>
<tr>
<td>Total support &amp; revenues</td>
<td>39,358,808</td>
<td>20,124,058</td>
<td>59,482,866</td>
<td>17,897,437</td>
</tr>
</tbody>
</table>

### Expenses

| Program services:        |                                  |                             |            |            |
| Grants                   | 18,468,664                       | -                           | 18,468,664 | 16,566,234 |
| Unexecuted prior year grants | 3,824,811                      | -                           | 3,824,811  | 325,000    |
| Other                    | 2,445,626                        | -                           | 2,445,626  | 2,237,637  |
| Total program services   | 17,089,479                       | -                           | 17,089,479 | 18,478,871 |

| Support services:        |                                  |                             |            |            |
| Fund raising             | 1,817,730                        | -                           | 1,817,730  | 2,163,272  |
| Management & general     | 949,103                          | -                           | 949,103    | 538,963    |
| Total supporting services | 2,766,833                       | -                           | 2,766,833  | 2,702,235  |
| Total expenses           | 19,856,312                       | -                           | 19,856,312 | 21,181,106 |

| Change in net assets     | 19,502,496                       | 20,124,058                  | 39,626,554 | 3,283,669  |
| Net assets, beginning of year | 5,226,794                        | 15,080,533                  | 20,307,327 | 23,590,996 |
| Net assets, end of year  | $ 24,729,290                     | 35,204,591                  | 59,933,881 | 20,307,327 |
100% Of Your Donation Funds Science

All fundraising and management expenses are underwritten by our founders, so your entire donation funds the most innovative drug research around the world.

We're proud to hold GuideStar's highest charity rating.
Alzheimer's Drug Discovery Foundation

Founded in 1998 by Leonard A. Lauder and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation (ADDF) is the only philanthropy solely focused on accelerating the development of drugs to prevent and treat Alzheimer's disease. Its venture philanthropy approach and scientific expertise allows the ADDF to support the most promising ideas around the world. And 100% of your donation funds drug research programs.

To learn more, visit AlzDiscovery.org.

57 West 57th Street, Suite 904 | New York, NY 10019 | 212.901.8000 | info@alzdiscovery.org